AU762758B2 - Gene encoding labyrinthin, a marker for cancer - Google Patents
Gene encoding labyrinthin, a marker for cancer Download PDFInfo
- Publication number
- AU762758B2 AU762758B2 AU29996/99A AU2999699A AU762758B2 AU 762758 B2 AU762758 B2 AU 762758B2 AU 29996/99 A AU29996/99 A AU 29996/99A AU 2999699 A AU2999699 A AU 2999699A AU 762758 B2 AU762758 B2 AU 762758B2
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- molecule
- acid sequence
- lab
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 61
- 201000011510 cancer Diseases 0.000 title claims description 39
- 108090000623 proteins and genes Proteins 0.000 title description 71
- 239000003550 marker Substances 0.000 title description 7
- 230000014509 gene expression Effects 0.000 claims description 34
- 229960005486 vaccine Drugs 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 23
- 239000002299 complementary DNA Substances 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 230000000692 anti-sense effect Effects 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 96
- 235000018102 proteins Nutrition 0.000 description 48
- 102000004169 proteins and genes Human genes 0.000 description 48
- 239000000427 antigen Substances 0.000 description 35
- 102000036639 antigens Human genes 0.000 description 35
- 108091007433 antigens Proteins 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 201000009030 Carcinoma Diseases 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 101150017124 lab gene Proteins 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000001520 comb Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 3
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002380 cytological effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 208000003849 large cell carcinoma Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- -1 aspartyl Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000010005 growth-factor like effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 101710125089 Bindin Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000399988 Carinoma Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 241000283014 Dama Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010072104 Fructose intolerance Diseases 0.000 description 1
- 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 1
- 208000033229 Immune-mediated cerebellar ataxia Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 241001435619 Lile Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000275031 Nica Species 0.000 description 1
- GFRROZIJVHUSKZ-FXGMSQOLSA-N OS I Natural products C[C@@H]1O[C@@H](O[C@H]2[C@@H](O)[C@@H](CO)O[C@@H](OC[C@@H](O)[C@@H](O)[C@@H](O)CO)[C@@H]2NC(=O)C)[C@H](O)[C@H](O)[C@H]1O GFRROZIJVHUSKZ-FXGMSQOLSA-N 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000031708 Saprospiraceae Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 235000005505 Ziziphus oenoplia Nutrition 0.000 description 1
- 244000104547 Ziziphus oenoplia Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 108010025220 aspartic acid 2-oxoglutarate-dependent dioxygenase Proteins 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- JNSGIVNNHKGGRU-JYRVWZFOSA-N diethoxyphosphinothioyl (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetate Chemical compound CCOP(=S)(OCC)OC(=O)C(=N/OC)\C1=CSC(N)=N1 JNSGIVNNHKGGRU-JYRVWZFOSA-N 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/040,485 US6166176A (en) | 1998-03-17 | 1998-03-17 | Cancer marker protein and peptides thereof |
| US09/040485 | 1998-03-17 | ||
| PCT/US1999/005365 WO1999047683A1 (en) | 1998-03-17 | 1999-03-11 | Gene encoding labyrinthin, a marker for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003204331A Division AU2003204331B2 (en) | 1998-03-17 | 2003-05-22 | Gene Encoding Labyrinthin, A Marker For Cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2999699A AU2999699A (en) | 1999-10-11 |
| AU762758B2 true AU762758B2 (en) | 2003-07-03 |
Family
ID=21911225
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU29996/99A Ceased AU762758B2 (en) | 1998-03-17 | 1999-03-11 | Gene encoding labyrinthin, a marker for cancer |
| AU2003204331A Ceased AU2003204331B2 (en) | 1998-03-17 | 2003-05-22 | Gene Encoding Labyrinthin, A Marker For Cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003204331A Ceased AU2003204331B2 (en) | 1998-03-17 | 2003-05-22 | Gene Encoding Labyrinthin, A Marker For Cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US6166176A (enExample) |
| EP (1) | EP1062346B1 (enExample) |
| JP (2) | JP2002512005A (enExample) |
| CN (2) | CN100372938C (enExample) |
| AP (1) | AP2000001917A0 (enExample) |
| AT (1) | ATE337400T1 (enExample) |
| AU (2) | AU762758B2 (enExample) |
| BR (1) | BR9908886A (enExample) |
| CA (1) | CA2323494A1 (enExample) |
| DE (1) | DE69932926T2 (enExample) |
| EA (1) | EA003735B1 (enExample) |
| IL (1) | IL138208A0 (enExample) |
| OA (1) | OA11487A (enExample) |
| WO (1) | WO1999047683A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6166176A (en) * | 1998-03-17 | 2000-12-26 | Immvarx, Inc. | Cancer marker protein and peptides thereof |
| US6835370B2 (en) | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
| US20030031670A1 (en) * | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| US20050123545A1 (en) * | 1999-11-08 | 2005-06-09 | Wands Jack R. | Diagnosis and treatment of malignant neoplasms |
| US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
| US7306919B1 (en) | 2001-10-31 | 2007-12-11 | Thornthwaite Jerry T | Antigen-antibody cancer recognition system |
| EP1536814A4 (en) * | 2002-07-03 | 2006-02-15 | Immunogen Inc | ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF |
| DE60324794D1 (de) * | 2003-09-04 | 2009-01-02 | Biomay Ag | Hypoallergene Polypeptide basierend auf aus Fisch gewonnenem Parvalbumin |
| EP1699485A4 (en) * | 2003-11-14 | 2007-12-19 | Massachusetts Inst Technology | ANTI-HYDROLYSATE ANTIBODIES AND ITS USES |
| CN100457922C (zh) * | 2005-10-20 | 2009-02-04 | 康哲医药研究(深圳)有限公司 | 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片 |
| RU2340896C1 (ru) * | 2007-05-17 | 2008-12-10 | Негосударственное научно-исследовательское учреждение "Биомедицинский центр" | Способ диагностики онкологических заболеваний |
| GB201002627D0 (en) | 2010-02-16 | 2010-03-31 | Loxbridge Res Llp | Aptamer based analyte detection method |
| TW202039536A (zh) * | 2018-12-13 | 2020-11-01 | 美商拉比林免疫治療美國有限公司 | 用於癌症免疫療法之基於拉比林(labyrinthin)之肽及其用途 |
| JP2022517329A (ja) * | 2019-01-08 | 2022-03-08 | ラビアールエックス イミュノロジック セラピューティクス （ユーエスエー） リミテッド | ラビリンチン又はその一部を標的とする構築物及びその使用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816402A (en) * | 1986-01-07 | 1989-03-28 | Northwestern University | Murine hybridoma and diagnostic antibody produced thereby |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5223604A (en) * | 1991-06-25 | 1993-06-29 | S.P.I. Synthetic Peptides Incorporated | Pseudomonas exoenzyme s peptide composition and method |
| US5728819A (en) * | 1996-08-02 | 1998-03-17 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
| US5994062A (en) | 1995-10-02 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Epithelial protein and DNA thereof for use in early cancer detection |
| US6166176A (en) * | 1998-03-17 | 2000-12-26 | Immvarx, Inc. | Cancer marker protein and peptides thereof |
| US6344548B1 (en) * | 1998-06-24 | 2002-02-05 | The Regents Of The University Of California | Diacylglycerol o-acyltransferase |
| US7135617B2 (en) * | 1998-07-02 | 2006-11-14 | Calgene Llc | Diacylglycerol acyl transferase proteins |
| US6100077A (en) * | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
| US20030161831A1 (en) * | 2001-02-23 | 2003-08-28 | Sylvaine Cases | Mono-and diacylglycerol acyltransferases and methods of use thereof |
| US7045326B2 (en) * | 2001-02-23 | 2006-05-16 | The Regents Of The University Of California | Mono- and diacylglycerol acyltransferases and methods of use thereof |
| CA2492205A1 (en) * | 2002-07-31 | 2004-02-05 | Monsanto Technology, Llc | Diacylglycerol acyltransferase nucleic acid sequences and associated products |
| US8685679B2 (en) * | 2004-11-04 | 2014-04-01 | E I Du Pont De Nemours And Company | Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms |
| US8507754B2 (en) * | 2009-01-31 | 2013-08-13 | University Of North Texas | Engineering lipids in vegetative tissues of plants |
| CA2804025C (en) * | 2010-06-28 | 2023-02-21 | Commonwealth Scientific And Industrial Research Organisation | Methods of producing lipids |
-
1998
- 1998-03-17 US US09/040,485 patent/US6166176A/en not_active Expired - Fee Related
-
1999
- 1999-03-11 CN CNB998061697A patent/CN100372938C/zh not_active Expired - Fee Related
- 1999-03-11 IL IL13820899A patent/IL138208A0/xx unknown
- 1999-03-11 WO PCT/US1999/005365 patent/WO1999047683A1/en not_active Ceased
- 1999-03-11 EP EP99911331A patent/EP1062346B1/en not_active Expired - Lifetime
- 1999-03-11 CA CA002323494A patent/CA2323494A1/en not_active Abandoned
- 1999-03-11 CN CNA2008100031485A patent/CN101260401A/zh active Pending
- 1999-03-11 AT AT99911331T patent/ATE337400T1/de not_active IP Right Cessation
- 1999-03-11 BR BR9908886-0A patent/BR9908886A/pt not_active Application Discontinuation
- 1999-03-11 JP JP2000536866A patent/JP2002512005A/ja active Pending
- 1999-03-11 EA EA200000845A patent/EA003735B1/ru not_active IP Right Cessation
- 1999-03-11 DE DE69932926T patent/DE69932926T2/de not_active Expired - Lifetime
- 1999-03-11 AU AU29996/99A patent/AU762758B2/en not_active Ceased
- 1999-03-11 AP APAP/P/2000/001917A patent/AP2000001917A0/en unknown
-
2000
- 2000-09-12 US US09/659,521 patent/US6727080B1/en not_active Expired - Fee Related
- 2000-09-18 OA OA1200000256A patent/OA11487A/en unknown
-
2003
- 2003-05-22 AU AU2003204331A patent/AU2003204331B2/en not_active Ceased
-
2004
- 2004-04-23 US US10/830,702 patent/US7329743B2/en not_active Expired - Fee Related
-
2008
- 2008-02-11 US US12/029,113 patent/US7635759B2/en not_active Expired - Fee Related
-
2009
- 2009-04-28 JP JP2009110164A patent/JP2009165492A/ja active Pending
- 2009-10-23 US US12/605,185 patent/US8163883B2/en not_active Expired - Fee Related
-
2010
- 2010-03-16 US US12/725,414 patent/US20100233711A1/en not_active Abandoned
- 2010-03-16 US US12/725,404 patent/US20110110963A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999047683A1 (en) | 1999-09-23 |
| DE69932926D1 (de) | 2006-10-05 |
| US7635759B2 (en) | 2009-12-22 |
| AU2999699A (en) | 1999-10-11 |
| IL138208A0 (en) | 2001-10-31 |
| US8163883B2 (en) | 2012-04-24 |
| BR9908886A (pt) | 2000-11-21 |
| JP2002512005A (ja) | 2002-04-23 |
| CA2323494A1 (en) | 1999-09-23 |
| JP2009165492A (ja) | 2009-07-30 |
| EP1062346A1 (en) | 2000-12-27 |
| DE69932926T2 (de) | 2007-05-24 |
| CN100372938C (zh) | 2008-03-05 |
| AP2000001917A0 (en) | 2000-09-30 |
| ATE337400T1 (de) | 2006-09-15 |
| US20080249284A1 (en) | 2008-10-09 |
| US20050208508A1 (en) | 2005-09-22 |
| OA11487A (en) | 2004-05-04 |
| US20100233711A1 (en) | 2010-09-16 |
| HK1033151A1 (en) | 2001-08-17 |
| CN1301302A (zh) | 2001-06-27 |
| WO1999047683A9 (en) | 1999-11-18 |
| EA200000845A1 (ru) | 2001-08-27 |
| US20100112582A1 (en) | 2010-05-06 |
| US6727080B1 (en) | 2004-04-27 |
| US20110110963A1 (en) | 2011-05-12 |
| US6166176A (en) | 2000-12-26 |
| CN101260401A (zh) | 2008-09-10 |
| US7329743B2 (en) | 2008-02-12 |
| EP1062346B1 (en) | 2006-08-23 |
| EA003735B1 (ru) | 2003-08-28 |
| AU2003204331B2 (en) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU762758B2 (en) | Gene encoding labyrinthin, a marker for cancer | |
| CA2281952C (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| ES2215376T3 (es) | Tadg-15: una proteasa de serina extracelular sobreexpresada en carcinomas de mama y ovario. | |
| ES2277432T3 (es) | Compuestos y metodos para terapia y diagnosis de cancer de pulmon. | |
| EP2298877A1 (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
| CA2380550A1 (en) | C type lectin transmembrane antigen expressed in human prostate cancer and uses thereof | |
| JP2014027932A (ja) | がん関連抗原 | |
| CA2187775A1 (en) | Method for molecular staging of prostate cancer | |
| EP1356093A2 (en) | Gene markers for lung cancer | |
| CN115707784A (zh) | Usp10在非小细胞肺癌患者的诊断和预后评估中的应用 | |
| CA2301902C (en) | Novel extracellular serine protease | |
| JPH08500731A (ja) | 診断法 | |
| KR20060133560A (ko) | 신규 혈청형 스트렙토코쿠스 뮤탄스 및 그 이용 | |
| CA2398064A1 (en) | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer | |
| NZ507014A (en) | A gene encoding a novel marker for cancer | |
| AU2008202039A1 (en) | Gene encoding labyrinthin, a marker for cancer | |
| TW200808973A (en) | Granulysin and uses thereof | |
| CN105483274B (zh) | 与椎间盘退行性病变相关的基因标志物 | |
| HK1033151B (en) | Gene encoding labyrinthin, a marker for cancer | |
| HK1122838A (en) | A gene encoding for a novel marker for cancer | |
| MXPA00008836A (en) | Gene encoding labyrinthin, a marker for cancer | |
| WO2005123127A2 (en) | Methods for treating cancer using prss15 as a target | |
| CA2388709A1 (en) | Gene upregulated in cancers of the prostate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: IMMVARX, INC. Free format text: THE FORMER OWNER WAS: JAMES A. RADOSEVICH |
|
| SREP | Specification republished | ||
| FGA | Letters patent sealed or granted (standard patent) |